Clinical OMICS

MAY-JUN 2019

Healthcare magazine for research scientists, labs, pathologists, hospitals, cancer centers, physicians and biopharma companies providing news articles, expert interviews and videos about molecular diagnostics in precision medicine

Issue link: https://clinicalomics.epubxp.com/i/1117801

Contents of this Issue

Navigation

Page 42 of 50

www.clinicalomics.com May/June 2019 Clinical OMICs 41 T here are smart cars, smart refrigerators, smart TVs, and of course smartphones. So why not a smart tampon? Creating one is the focus of NextGen Jane, a diagnostic startup focused on reproductive health technology. The company—which calls itself "Jane" for short— has created a technology designed to allow users to collect men- strual and cervicovaginal samples with an everyday house- hold product, preserve nucleic acids and other analytes important for disease detection, and ship them off to a lab for in-depth sequencing analysis and disease detection. "The NextGen Jane system allows for superior preserva- tion of DNA and RNA of cells from the endometrium, cer- vix, fallopian tubes, and ovaries. NextGen Jane then builds proprietary algorithms to correlate specific genomic sig- nals found in cells shed from your body to specific disease states," said Ridhi Tariyal, co-founder and CEO. On April 1, NextGen Jane announced the completion of a $9 million Series A financing. Material Impact led the round, along with Access Industries, Viking Global Investors, Lim- inal Ventures, and several angel investors. The 10 angels included two notable researchers—George Church, Ph.D., of Harvard Medical School, and Stephen Quake, Ph.D., of Stanford University. NextGen Jane said the proceeds will enable the company to position itself for commercialization of its technology some time in 2020. The company sees several factors as driving market need. Many female reproductive disorders present with generic symptoms that are difficult to differentiate; women's pain is sometimes dis- missed or normalized, complicating efforts at diagnosis; and some parts of the U.S. are expe- riencing OB-GYN shortages. The company also cites a desire by women for alternatives to in-clinic, invasive, and expensive conventional methods of diagnosing reproduc- tive disorders. O negevity Health launched in January, positioning itself as a provider of consumer-friendly health recommen- dations based on integrated analysis of customers' longitu- dinal blood, genetics, and gut microbiome profiles through the company's multi-omic AI platform. "Onegevity is focused on solving the limitations of one-dimensional health analytics, i.e., only blood or genet- ics alone," Joel Dudley, Ph.D., Onegevity co-founder and scientific advisor, told Clinical OMICs. By integrating untargeted analyses of longitudinal bio- markers—including blood, metabolomics, the human genome, and microbiome profiles— Onegevity aims to offer consumers a comprehensive molecular portrait through its Health Intelligence Platform. The company also partners with nutrition company Thorne, and its network of 35,000 physicians, to offer cus- tomers testing and analytical tools designed to improve preventative care and lower healthcare costs. Customers receive customized lifestyle, exercise, and diet recommen- dations, including clinically-studied supplements, and pre- and probiotics. Behind the science and analysis at Onegevity are personal stories. Dudley has Crohn's disease; his wife has irritable bowel syndrome; and family members of Onegevity's other scientific co-founder, Chris Mason, Ph.D., have struggled with various gastrointestinal issues. Onegevity's first product, GutBio, combines its advanced Metagenome+ sequencing technology with AI-based per- sonalized insights. GutBio aims to give customers what the company says is the most comprehensive, accurate, and insightful picture of their microbiome health, with recom- mendations based on research, technology, science, and machine learning. "With a holistic picture of health, Onegevity can under- stand how changes at one level (e.g., the gut microbiome) can drive healthy changes at another (e.g., blood) and pro- vide the user with metrics based on data from other individ- uals with a similar profile," Dudley added Onegevity will soon expand services to include whole-ge- nome sequencing and blood testing, plus personalized products and services for new populations. It is working exclusively with partner Drawbridge Health to develop the OneDraw blood sampling system, designed to enable con- venient and nearly painless blood-testing. RIDHI TARIYAL Co-founder and CEO of NextGen Jane JOEL DUDLEY Co-founder and scientific advisor, Onegevity

Articles in this issue

Links on this page

Archives of this issue

view archives of Clinical OMICS - MAY-JUN 2019